Section 5 - Psychopharmacology
Published online by Cambridge University Press: 19 October 2021
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Violence in Psychiatry , pp. 177 - 251Publisher: Cambridge University PressPrint publication year: 2016
References
References
Volavka, J. Neurobiology of Violence, 2nd edn. Washington, DC: American Psychiatric Publishing, Inc.; 2002.Google Scholar
Stroup, TS, McEvoy, JP, Swartz, MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull. 2003; 29(1): 15–31.CrossRefGoogle ScholarPubMed
Lieberman, JA, Stroup, TS, McEvoy, JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005; 353(12): 1209–1223.CrossRefGoogle ScholarPubMed
Swanson, JW, Swartz, MS, Van Dorn, RA, et al. A national study of violent behavior in persons with schizophrenia. Arch. Gen. Psychiatry. 2006; 63(5): 490–499.CrossRefGoogle ScholarPubMed
Fazel, S, Langstrom, N, Hjern, A, Grann, M, Lichtenstein, P. Schizophrenia, substance abuse, and violent crime. JAMA. 2009; 301(19): 2016–2023.CrossRefGoogle Scholar
Kay, SR, Opler, LA, Lindenmayer, JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry. 1989; 155(Suppl 7): 59–65.CrossRefGoogle Scholar
Witt, K, van Dorn, R, Fazel, S. Risk factors for violence in psychosis: systematic review and meta-regression analysis of 110 studies. PLoS One. 2013; 8(2): e55942.CrossRefGoogle ScholarPubMed
Volavka, J, Czobor, P, Derks, EM, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J. Clin. Psychiatry. 2011; 72(7): 955–961.CrossRefGoogle Scholar
Kay, SR, Opler, LA, Fiszbein, A. Positive and Negative Syndrome Scale (PANSS) rating manual. 1986. Unpublished work.CrossRefGoogle Scholar
Little, RC, Milliken, GA, Stroup, WW, Wolfinger, RD, Schabenberger, O. SAS for Mixed Models, 2nd edn. Cary, NC: SAS Press; 2006.Google Scholar
Swanson, JW, Swartz, MS, Van Dorn, RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J. Psychiatry. 2008; 193(1): 37–43.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.CrossRefGoogle ScholarPubMed
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility in treatment resistant patients with schizophrenia and schizoaffective disorder. Psychiatr. Serv. 2001; 52(11): 1510–1514.CrossRefGoogle Scholar
Czobor, P, Volavka, J, Meibach, RC. Effect of risperidone on hostility in schizophrenia. J. Clin. Psychopharmacol. 1995; 15(4): 243–249.CrossRefGoogle Scholar
Volavka, J, Czobor, P, Citrome, L, et al. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies. J. Clin. Psychiatry. 2005; 66(11): 1362–1366.CrossRefGoogle Scholar
Citrome, L, Volavka, J, Czobor, P, et al. Efficacy of ziprasidone against hostility in schizophrenia: post hoc analysis of randomized, openlabel study data. J. Clin. Psychiatry. 2006; 67(4): 638–642.CrossRefGoogle Scholar
Kinon, BJ, Roychowdhury, SM, Milton, DR, Hill, AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J. Clin. Psychiatry. 2001; 62(Suppl 2): 17–21.Google Scholar
Arango, C, Bernardo, M. The effect of quetiapine on aggression and hostility in patients with schizophrenia. Hum. Psychopharmacol. 2005; 20(4): 237–241.CrossRefGoogle ScholarPubMed
Chengappa, KN, Goldstein, JM, Greenwood, M, John, V, Levine, J. A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin. Ther. 2003; 25(2): 530–541.CrossRefGoogle ScholarPubMed
Volavka, J, Swanson, JW, Citrome, LL. Understanding and managing violence in schizophrenia. In: Lieberman, JA, Murray, RM, eds. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management, 2nd edn. New York: Oxford University Press; 2012: 262–290.Google Scholar
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000; 321(7273): 1371–1376.CrossRefGoogle Scholar
Moller, HJ. Do effectiveness (“real world”) studies on antipsychotics tell us the real truth? Eur. Arch. Psychiatry Clin. Neurosci. 2008; 258(5): 257–270.CrossRefGoogle ScholarPubMed
Kinon, BJ, Volavka, J, Stauffer, V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J. Clin. Psychopharmacol. 2008; 28(4): 392–400.CrossRefGoogle ScholarPubMed
Citrome, L, Holt, RI, Walker, DJ, Hoffmann, VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin. Drug Investig. 2011; 31(7): 455–482.CrossRefGoogle Scholar
Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 2008; 62(8): 1237–1245.CrossRefGoogle ScholarPubMed
Swanson, JW, Van Dorn, RA, Swartz, MS, et al. Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems. Law Hum. Behav. 2008; 32(3): 228–240.CrossRefGoogle Scholar
Laajasalo, T, Salenius, S, Lindberg, N, Repo-Tiihonen, E, Hakkanen-Nyholm, H. Psychopathic traits in Finnish homicide offenders with schizophrenia. Int. J. Law Psychiatry. 2011; 34(3–4): 324–330.CrossRefGoogle Scholar
Abushua’leh, K, bu-Akel, A. Association of psychopathic traits and symptomatology with violence in patients with schizophrenia. Psychiatry Res. 2006; 143(2–3): 205–211.CrossRefGoogle Scholar
References
Ingenhoven, T, Lafay, P, Rinne, T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J. Clin. Psychiatry. 2010; 71(1): 14–25.CrossRefGoogle ScholarPubMed
Lieb, K, Völlm, B, Rücker, G, et al. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br. J. Psychiatry. 2010; 196(1): 4–12.CrossRefGoogle ScholarPubMed
Stoffers, JBA, Vo¨llm, G, Ru¨cker, A, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010; (6): CD005653.CrossRefGoogle Scholar
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J. Clin. Psychiatry. 2006; 67(7): 1042–1046.CrossRefGoogle ScholarPubMed
Hilger, E, Barnas, C, Kasper, S. Quetiapine in the treatment of borderline personality disorder. World J. Biol. Psychiatry. 2003; 4(1): 42–44.CrossRefGoogle ScholarPubMed
Villeneuve, E, Lemelin, S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J. Clin. Psychiatry. 2005; 66(10): 1298–1303.CrossRefGoogle ScholarPubMed
Nickel, M, Muehlbacher, M, Nickel, C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry. 2006; 163(5): 833–838.CrossRefGoogle Scholar
Bellino, S, Bozzatello, P, Rinaldi, C, Bogetto, F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress. Res. Treat. 2011; 2011: 680194.Google ScholarPubMed
Grootens, KP, Verkes, RJ. Emerging evidence for the use of atypical antipsychotics in borderline personality disorder. Pharmacopsychiatry. 2005; 38(01): 20–23.CrossRefGoogle ScholarPubMed
Bogenschutz, MP, Nurnberg, G. Olanzapine versus placebo in the treatment of borderline personality disorder. J. Clin. Psychiatry. 2004; 65(1): 104–109.CrossRefGoogle ScholarPubMed
Linehan, MM, McDavid, JD, Brown, MZ, Sayrs, JH, Gallop, RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J. Clin. Psychiatry. 2008; 69(6): 999–1005.CrossRefGoogle ScholarPubMed
Schulz, CS, Camlin, KL, Berry, SA, Jesberger, JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol. Psychiatry. 1999; 46(10): 1429–1435.CrossRefGoogle Scholar
Zanarini, MC, Frankenburg, FR, Parachini, EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine–fluoxetine combination in women with borderline personality disorder. J. Clin. Psychiatry. 2004; 65(7): 903–907.CrossRefGoogle ScholarPubMed
Zanarini, MC, Frankenburg, FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo controlled pilot study. J. Clin. Psychiatry. 2001; 62(11): 849–854.CrossRefGoogle ScholarPubMed
Keshavan, M, Shad, M, Soloff, P, Schooler, N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr. Res. 2004; 71(1): 97–101.CrossRefGoogle ScholarPubMed
Koenigsberg, HW, Reynolds, D, Goodman, M, et al. Risperidone in the treatment of schizotypal personality disorder. J. Clin. Psychiatry. 2003; 64(6): 628–634.CrossRefGoogle ScholarPubMed
Rocca, P, Marchiaro, L, Cocuzza, E, Bogetto, F. Treatment of borderline personality disorder with risperidone. J. Clin. Psychiatry. 2002; 63(3): 241–244.CrossRefGoogle ScholarPubMed
Vauquelin, G, Bostoen, S, Vanderheyden, P, Seeman, P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch. Pharmacol. 2012; 385(4): 337–372.CrossRefGoogle ScholarPubMed
Fakra, E, Azorin, J. Clozapine for the treatment of schizophrenia. Expert Opin. Pharmacother. 2012; 13(3): 1923–1935.CrossRefGoogle ScholarPubMed
Chakos, M, Lieberman, J, Hoffman, E, Bradford, D, Sheitman, B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001; 158(4): 518–526.CrossRefGoogle Scholar
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45(9): 789–796.CrossRefGoogle ScholarPubMed
Meltzer, Herbert Y. Treatment-resistant schizophrenia-the role of clozapine. Curr. Med. Res. Opin. 1997; 14(1): 1–20.CrossRefGoogle Scholar
Chengappa, KN, Ebeling, T, Kang, JS, Levine, J, Parepally, H. Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J. Clin. Psychiatry. 1999; 60(7): 477–484.CrossRefGoogle ScholarPubMed
Vohra, AK. Treatment of severe borderline personality disorder with clozapine. Indian J. Psychiatry. 2010; 52(3): 267–269.CrossRefGoogle Scholar
Benedetti, F, Sforzini, L, Colombo, C, Maffei, C, Smeraldi, E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J. Clin. Psychiatry. 1998; 59(3): 103–107.CrossRefGoogle ScholarPubMed
Swinton, M. Clozapine in severe borderline personality disorder. The Journal of Forensic Psychiatry. 2001; 12(3): 580–591.CrossRefGoogle Scholar
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr. Psychiatry. 1993; 34(6): 402–405.CrossRefGoogle Scholar
Buckley, P, Bartell, J, Donenwirth, K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull. Am. Acad. Psychiatry Law. 1995; 23(4): 607–611.Google ScholarPubMed
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012; 15(9): 1351–1371.CrossRefGoogle Scholar
Chengappa, KNR, Vasile, J, Levine, J, et al. Clozapine: its impact on aggressive behaviour among patients in a state psychiatric hospital. Schizophr. Res. 2002; 53(1–2): 1–6.CrossRefGoogle Scholar
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv. 2001; 52(11): 1510–1514.CrossRefGoogle Scholar
Dalal, B, Larkin, E, Leese, M, Taylor, PJ. Clozapine treatment of longstanding schizophrenia and serious violence: a two-year follow-up study of the first 50 patients treated with clozapine in Rampton high security hospital. Crim. Behav. Ment. Health. 1999; 9(2): 168–178.CrossRefGoogle Scholar
Rabinowitz, J, Avnon, M, Rosenberg, V. Effect of clozapine on physical and verbal aggression. Schizophr. Res. 1996; 22(3): 249–255.CrossRefGoogle ScholarPubMed
Ratey, JJ, Leveroni, C, Kilmer, D, Gutheil, C. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J. Clin. Psychiatry. 1993; 54(6): 219–223.Google ScholarPubMed
Volavka, J. The effects of clozapine on aggression and substance abuse in schizophrenic patients. J. Clin. Psychiatry. 1999; 60(Suppl 12): 43–46.Google ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.CrossRefGoogle ScholarPubMed
Hare, RD. Manual for the Revised Psychopathy Checklist (1st edn). 1991. Toronto, ON, Canada: Multi-Health Systems. URL for other refs: http://scholar.google.co.uk/scholar?hl5en&q5hare1checklist& btnG5&as_sdt51%2C5&as_sdtp5Google Scholar
Hart, SD, Cox, DN, Hare, RD. The Hare Psychopathy Checklist: Screening Version (PCL: SV). Toronto, ON, Canada: Multi-HealthSystems, Inc.; 1995.Google Scholar
Guy, W. The Clinical Global Impression Scale. In: Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev. edn. Rockville, MD: U.S. Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976:218–222.Google Scholar
Frankenburg, FR, Zanarini, MC. Clozapine treatment of borderline patients: a preliminary study. Compr. Psychiatry. 1993; 34(6): 402–405.CrossRefGoogle ScholarPubMed
Binks, CA, Fenton, M, McCarthy, L, et al. Psychological therapies for people with borderline personality disorder. Cochrane Database Syst. Rev. 2006; (1): CD005652.Google Scholar
Soloff, PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioural dysregulation. Bull. Menninger Clin. 1997; 62(2): 195–214.Google Scholar
Webster, C, Douglas, K, Eaves, D, Hart, S. HCR-20: Assessing Risk for Violence. Version 2; 1992. Burnaby, BC, Canada: Mental Health, Law and Policy Institute, Simon Fraser University.Google Scholar
World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992; 50.Google Scholar
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn, text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
Glazer, GM, Dickson, RA. Clozapine reduces violence and persistent aggression in schizophrenia. J. Clin. Psychiatry. 1998; 59(Suppl 3): 8–14.Google Scholar
Spina, E, Avenoso, A, Facciol`a, G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl.). 2000; 148(1): 83–89.CrossRefGoogle ScholarPubMed
Humbert-Claude, M, Davenas, E, Gbahou, F, Vincent, L, Arrang, JM. Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl.). 2012; 220(1): 225–241.CrossRefGoogle ScholarPubMed
Harrison, AA, Everitt, BJ, Robbins, TW. Central 5-HT depletion enhances impulsive responding without affecting the accuracy of attentional performance: interactions with dopaminergic mechanisms. Psychopharmacology (Berl.). 1997; 133(4): 329–342.CrossRefGoogle ScholarPubMed
Vukhac, K, Sankoorika, EL, Yanyan Wang. Dopamine D2L receptor and age-related reduction in offensive aggression. Neuroreport. 2001; 12(5): 1035–1038.CrossRefGoogle Scholar
Wade, TR, Wit, HD, Richards, JB. Effects of dopaminergic drugs on delayed reward as a measure of impulsive behaviour in rats. Psychopharmacology (Berl.). 2000; 150(1): 90–101.Google Scholar
Chotai, J, Kullgren, J, Åsberg, M. CSF monoamine metabolites in relation to the diagnostic interview for borderline patients (DIB). Neuropsychobiology. 1998; 38(4): 207–212.CrossRefGoogle Scholar
Coccaro, EF, Silk, KR, ed. Neurotransmitter function in personality disorders. In: Biology of Personality Disorders. Washington, DC: American Psychiatric Press; 1998: 1–25.Google Scholar
Friedel, RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004; 29(6): 1029–1039.CrossRefGoogle ScholarPubMed
Adams, DB. Brain mechanisms for offence, defence, and submission. Behav. Brain Sci. 1979; 2(2): 201–213.CrossRefGoogle Scholar
Berman, ME, Tracy, JI, Coccaro, EF. The serotonin hypothesis of aggression revisited. Clin. Psychol. Rev. 1997; 17(6): 651–665.CrossRefGoogle ScholarPubMed
Brown, GL. Aggression, suicide, and serotonin: relationships of CSF amine metabolites. Am. J. Psychiatry. 1982; 139(6): 741–746.Google ScholarPubMed
de Boer, FS, Koolhaas, JM. 5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis. Eur. J. Pharmacol. 2005; 526(1–3): 125–139.CrossRefGoogle ScholarPubMed
Gowin, JL, Swann, AC, Moeller, FG, Lane, SD. Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology (Berl.). 2010; 210(4): 521–531.CrossRefGoogle ScholarPubMed
Miczek, KA, Fish, EW, Joseph, F, De Almeida, RM. Social and neural determinants of aggressive behaviour: pharmacotherapeutic targets at serotonin, dopamine and γ-aminobutyric acid systems. Psychopharmacology (Berl.). 2002; 163(3): 434–458.CrossRefGoogle ScholarPubMed
Moss, HB, Yao, JK, Panzak, GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol. Psychiatry. 1990; 28(4): 325–338.CrossRefGoogle Scholar
Constantino, JN, Morris, JA, Murphy, DL. CSF 5-HIAA and family history of antisocial personality disorder in newborns. Am. J. Psychiatry. 1997; 154(2): 1771–1773.CrossRefGoogle ScholarPubMed
Krakowski, M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning. J Neuropsychiatry Clin Neurosci. 2003; 15(3): 294–305.CrossRefGoogle ScholarPubMed
Umukoro, S, Aladeokin, AC, Eduviere, AT. Aggressive behavior: a comprehensive review of its neurochemical mechanisms and management. Aggression and Violent Behavior. 2012; 18(2): 195–203.CrossRefGoogle Scholar
Paris, P. Antisocial and borderline personality disorders: two separate diagnoses or two aspects of the same psychopathology? Compr. Psychiatry. 1997; 38(4): 237–242.CrossRefGoogle ScholarPubMed
Bateman, AW, Tyrer, P. Psychological treatment for personality disorders. Advances in Psychiatric Treatment. 2004; 10(5): 378–388.CrossRefGoogle Scholar
Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of pharmacotherapies for borderline personality disorder. CNS Drugs. 2008; 22(8): 671–692.CrossRefGoogle ScholarPubMed
Nelson, KJ, Schulz, CS. Treatment advances in borderline personality disorder. Psychiatric Annals. 2012; 42(2): 59–64.CrossRefGoogle Scholar
Dolan, M. Psychopathic personality in young people. Advances in Psychiatric Treatment. 2004; 10(6): 466–473.CrossRefGoogle Scholar
Hare, RD. Psychopathy, affect and behaviour. In: Cooke, DJ, Forth, AE, Hare, RD, eds. Psychopathy: Theory, Research and Implications for Society. Dordrecht, the Netherlands: Springer; 1998: 105–137.CrossRefGoogle Scholar
Salekin, RT, Rogers, R, Sewell, KW. A review and meta-analysis of the Psychopathy Checklist and Psychopathy Checklist-Revised: predictive validity of dangerousness. Clinical Psychology: Science and Practice. 1996; 3(3): 203–215.Google Scholar
Buckholtz, JW, Treadway, MT, Cowan, RL, et al. Mesolimbic dopamine reward system hypersensitivity in individuals with psychopathic traits. Nat. Neurosci. 2010; 13(4): 419–421.CrossRefGoogle ScholarPubMed
Dolan, MC, Anderson, IM. The relationship between serotonergic function and the Psychopathy Checklist: Screening Version. J. Psychopharmacol. 2003; 17(2): 216–222.CrossRefGoogle Scholar
Soderstrom, H, Blennow, K, Sjodin, AK, Forsman, A. New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J. Neurol. Neurosurg. Psychiatry. 2003; 74(7): 918–921.CrossRefGoogle ScholarPubMed
Barkataki, I, Kumar, V, Das, M, Taylor, P, Sharma, T. Volumetric structural brain abnormalities in men with schizophrenia or antisocial personality disorder. Behav. Brain Res. 2006; 169(2): 239–247.CrossRefGoogle ScholarPubMed
Kumari, V, Das, M, Taylor, PJ, et al. Neural and behavioural responses to threat in men with a history of serious violence and schizophrenia or antisocial personality disorder. Schizoph. Res. 2009; 110(1–3): 47–58.CrossRefGoogle ScholarPubMed
Yang, Y, Raine, R. Prefrontal structural and functional brain imaging findings in antisocial, violent, and psychopathic individuals: a meta-analysis. Psychiatry Res. 2009; 174(2): 81–88.CrossRefGoogle ScholarPubMed
Chopra, HD, Beatson, JA. Psychotic symptoms in borderline personality disorder. Am. J. Psychiatry. 1986; 143(12): 1605–1607.Google ScholarPubMed
Kendal, T, Pilling, S, Tyrer, P, et al. Guidelines: Borderline and Antisocial Personality Disorders: Summary of NICE Guidance. BMJ. 2009; 338(7689): 293–295.Google Scholar
Volavka, J, Citrome, L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr. Res. 1999; 35(Suppl): S23–S33.CrossRefGoogle ScholarPubMed
References
Fakra, E, Azorin, JM. Clozapine for the treatment of schizophrenia. Expert Opin. Pharmacother. 2012; 13(13): 1923–1935.CrossRefGoogle ScholarPubMed
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988; 45(9): 789–796.CrossRefGoogle ScholarPubMed
Rosenheck, R, Cramer, J, Xu, W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N. Engl. J. Med. 1997; 337(12): 809–815.CrossRefGoogle ScholarPubMed
Baldessarini, RJ, Frankenburg, FR. Clozapine—a novel antipsychotic agent. N. Engl. J. Med. 1991; 324(11): 746–754.Google Scholar
Porcelli, S, Balzarro, B, Serretti, A. Clozapine resistance: augmentation strategies. Eur. Neuropsychopharmacol. 2012; 22(3): 165–182.CrossRefGoogle ScholarPubMed
Stahl, SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J. Clin. Psychiatry. 1999; 60(7): 425–426.CrossRefGoogle Scholar
Stahl, SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr. Scand. 2002; 106(5): 321–322.CrossRefGoogle Scholar
Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr. Scand. 2012; 125(5): 349–351.CrossRefGoogle Scholar
Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev. Psiquiatr. Salud Ment. 2013; 6(3): 97–100.CrossRefGoogle Scholar
Pai, NB, Laidlaw, M, Vella, SC. Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the “real world.” Acta Psychiatr. Scand. 2012; 126(1): 40–46.CrossRefGoogle Scholar
Zink, M, Englisch, S, Meyer-Lindenberg, A. Polypharmacy in schizophrenia. Curr. Opin. Psychiatry. 2010; 23(2): 103–111.CrossRefGoogle Scholar
Correll, CU, Rummel-Kluge, C, Corves, C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009; 35(2): 443–457.CrossRefGoogle ScholarPubMed
Buchanan, RW, Kirkpatrick, B, Bryant, N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am. J. Psychiatry. 1996; 153(12): 1625–1627.Google ScholarPubMed
Wetzel, H, Anghelescu, I, Szegedi, A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychopharmacol. 1998; 18(1): 2–9.CrossRefGoogle Scholar
Berk, M, Gama, CS, Sundram, S, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum. Psychopharmacol. 2009; 24(3): 233–238.CrossRefGoogle Scholar
Zoccali, R, Muscatello, MR, Cedro, C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 2004; 19(2): 71–76.CrossRefGoogle ScholarPubMed
Tiihonen, J, Hallikainen, T, Ryynänen, OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry. 2003; 54(11): 1241–1248.CrossRefGoogle ScholarPubMed
Goff, DC, Keefe, R, Citrome, L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J. Clin. Psychopharmacol. 2007; 27(6): 582–589.CrossRefGoogle ScholarPubMed
Muscatello, MR, Bruno, A, Pandolfo, G, et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J. Psychopharmacol. 2011; 25(5): 667–674.CrossRefGoogle ScholarPubMed
Small, JG, Klapper, MH, Malloy, FW, Steadman, TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J. Clin. Psychopharmacol. 2003; 23(3): 223–228.CrossRefGoogle ScholarPubMed
Evins, AE, Fitzgerald, SM, Wine, L, et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry. 2000; 157(5): 826–828.CrossRefGoogle Scholar
Heresco-Levy, U, Javitt, DC, Ermilov, M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch. Gen. Psychiatry. 1999; 56(1): 29–36.CrossRefGoogle ScholarPubMed
Assion, HJ, Reinbold, H, Lemanski, S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008; 41(1): 24–28.CrossRefGoogle Scholar
Shiloh, R, Zemishlany, Z, Aizenberg, D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br. J. Psychiatry. 1997; 171: 569–573.CrossRefGoogle Scholar
Munro, J, Matthiasson, P, Osborne, S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr. Scand. 2004; 110(4): 292–298.CrossRefGoogle ScholarPubMed
Zink, M, Knopf, U, Henn, FA, Thome, J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia—case reports and review of the literature. Pharmacopsychiatry. 2004; 37(1): 26–31.Google ScholarPubMed
Kämpf, P, Agelink, MW, Naber, D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry. 2005; 38(1): 39–40.CrossRefGoogle Scholar
Walsh, E, Buchanan, A, Fahy, T. Violence and schizophrenia: examining the evidence. Br. J. Psychiatry. 2002; 180: 490–495.CrossRefGoogle ScholarPubMed
Wessely, S. The Camberwell Study of Crime and Schizophrenia. Soc. Psychiatry Psychiatr. Epidemiol. 1998; 33(Suppl 1): S24–S28.CrossRefGoogle Scholar
Taylor, PJ, Estroff, SE. Schizophrenia and violence. In: Hirsch, FR, Weinberger, DR, eds. Schizophrenia, 2nd edn. Oxford, UK: Blackwell Science Ltd.; 2007; 30: 591–612.Google ScholarPubMed
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services. 2001; 52(11): 1510–1514.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, et al. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.CrossRefGoogle ScholarPubMed
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012; 15(9): 1351–1371.CrossRefGoogle ScholarPubMed
Guy, W. The Clinical Global Impression Scale. In: Guy, W, ed. ECDEU Assessment Manual for Psychopharmacology –Rev. edn. Rockville, MD: US Department of Health, Education and Welfare, ADAMHA, MIMH Psychopharmacology Research Branch; 1976: 218–222.Google Scholar
Webster, C, Douglas, K, Eaves, D, Hart, S. HCR-20: Assessing Risk for Violence. Version 2. Burnaby, BC, Canada: Mental Health, Law and Policy Institute, Simon Fraser University.Google Scholar
Genç, Y, Taner, E, Candansayar, S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv. Ther. 2007; 24(1): 1–13.CrossRefGoogle ScholarPubMed
Ziegenbein, M, Sieberer, M, Kuenzel, HE, Kropp, S. Augmentation of clozapine with amisulpride in patients with treatment-resistant schizophrenia: an open clinical study. German Journal of Psychiatry. 2006; 9(1): 17–21.Google Scholar
Zink, M, Kuwilsky, A, Krumm, B, Dressing, H. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J. Psychopharmacol. 2009; 23(3): 305–314.CrossRefGoogle ScholarPubMed
Kuwilsky, A, Krumm, B, Englisch, S, et al. Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry. 2010; 43(6): 216–220.CrossRefGoogle ScholarPubMed
Taylor, DM, Smith, L. Augmentation of clozapine with a second antipsychotic—a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr. Scand. 2009; 119(6): 419–425.CrossRefGoogle ScholarPubMed
Chang, JS, Ahn, YM, Park, HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2008; 69(5): 720–731.CrossRefGoogle ScholarPubMed
Sommer, IE, Begemann, MJ, Temmerman, A, Leucht, S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr. Bull. 2012; 38(5): 1003–1011.CrossRefGoogle Scholar
Vauquelin, G, Bostoen, S, Vanderheyden, P, Seeman, P. Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn Schmiedebergs Arch. Pharmacol. 2012; 385(4): 337–372.CrossRefGoogle Scholar
Leucht, S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int. J. Neuropsychopharmacol. 2004; 7(Suppl 1): S15–S20.CrossRefGoogle ScholarPubMed
Scatton, B, Claustre, Y, Cudennec, A, et al. Amisulpride: from animal pharmacology to therapeutic action. Int. Clin. Psychopharmacol. 1997; 12(Suppl 2): S29–S36.CrossRefGoogle ScholarPubMed
Vernaleken, I, Siessmeier, T, Buchholz, HG, et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int. J. Neuropsychopharmacol. 2004; 7(4): 421–430.CrossRefGoogle Scholar
Abbas, AI, Hedlund, PB, Huang, XP, et al. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl.). 2009; 205(1): 119–128.CrossRefGoogle ScholarPubMed
Perrault, G, Depoortere, R, Morel, E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997; 280(1): 73–82.Google ScholarPubMed
Bowskill, SV, Patel, MX, Handley, SA, Flanagan, RJ. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002–2010. Hum. Psychopharmacol. 2012; 27(5): 507–513.CrossRefGoogle Scholar
Nordström, AL, Farde, L, Halldin, C. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology (Berl.). 1993; 110(3): 365–367.CrossRefGoogle ScholarPubMed
Kapur, S, Zipursky, RB, Remington, G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry. 1999; 156(2): 286–293.Google Scholar
Buckley, P, Bartell, J, Donenwirth, K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull. Am. Acad. Psychiatry Law. 1995; 23(4): 607–611.Google ScholarPubMed
Wilson, WH. Clinical review of clozapine treatment in a state hospital. Hosp. Community Psychiatry. 1992; 43(7): 700–703.Google Scholar
Umukoro, S, Aladeokin, AC, Eduviere, AT. Aggressive behavior: a comprehensive review of its neurochemical mechanisms and management. Aggression and Violent Behavior. 2013; 18(2): 195–203.CrossRefGoogle Scholar
Nelson, RJ, Trainor, BC. Neural mechanisms of aggression. Nat. Rev. Neurosci. 2007; 8(7): 536–546.CrossRefGoogle ScholarPubMed
Lieberman, JA, Safferman, AZ, Pollack, S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry. 1994; 151(12): 1744–1752.Google Scholar
Fabrazzo, M, La Pia, S, Monteleone, P, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 2002; 27(6): 1050–1055.CrossRefGoogle Scholar
Schulte, PF. What is an adequate trial with clozapine? Clin. Pharmacokinet. 2003; 42(7): 607–618.CrossRefGoogle ScholarPubMed
Wilson, WH. Time required for initial improvement during clozapine treatment of refractory schizophrenia. Am. J. Psychiatry. 1996; 157(7): 951–952.Google Scholar
Junginger, J, Parks-Levy, J, McGuire, L. Delusions and symptom-consistent violence. Psychiatr. Serv. 1998; 49(2): 218–220.CrossRefGoogle ScholarPubMed
Nolan, KA, Volavka, J, Czobor, P, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J. Psychiatr. Res. 2005; 39(1): 109–115.CrossRefGoogle Scholar
Volavka, J, Zito, JM, Vitrai, J, Czobor, P. Clozapine effects on hostility and aggression in schizophrenia. J. Clin. Psychopharmacol. 1993; 13(4): 287–288.CrossRefGoogle Scholar
Krakowski, MI, Czobor, P. Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. J. Clin. Psychiatry. 2012; 73(1): 74–80.CrossRefGoogle ScholarPubMed
Volavka, J, Citrome, L. Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns. Schizophr. Res. 1999; 35(Suppl): S23–S33.CrossRefGoogle ScholarPubMed
McGlashan, TH. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr. Bull. 1988; 14(4): 515–542.CrossRefGoogle Scholar
Revicki, DA, Luce, BR, Weschler, JM, Brown, RE, Adler, MA. Cost effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp. Community Psychiatry. 1990; 41(8): 850–854.Google ScholarPubMed
References
Swift, RH, Harrigan, EP, Cappelleri, JC, Kramer, D, Chandler, LP. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J. Psychiatr. Res. 2002; 36(2): 87–95.CrossRefGoogle Scholar
Lindenmayer, JP, Brown, E, Baker, RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr. Res. 2004; 68(2–3): 331–337.CrossRefGoogle ScholarPubMed
Yudofsky, SC, Silver, JM, Jackson, W, Endicott, J, Williams, D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am. J. Psychiatry. 1986; 143(1): 35–39.Google Scholar
Björkdahl, A, Olsson, D, Palmstierna, T. Nurses’ short-term prediction of violence in acute psychiatric intensive care. Acta Psychiatr. Scand. 2006; 113(3): 224–229.CrossRefGoogle ScholarPubMed
Kay, SR, Opler, LA, Fiszbein, A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 2000.Google Scholar
Citrome, L, Green, L. The dangerous agitated patient: what to do right now. Postgrad. Med. 1990; 87(2): 231–236.CrossRefGoogle Scholar
Citrome, L. Agitation III: pharmacologic treatment of agitation. In: Glick, RL, Berlin, JS, Fishkind, A, Zeller, S, eds. Emergency Psychiatry: Principles and Practice. Baltimore, MD: Lippincott Williams & Wilkins, Wolters Kluwer Health; 2008: 137–147.Google Scholar
Regier, DA, Farmer, ME, Rae, DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264(19): 2511–2518.CrossRefGoogle ScholarPubMed
Battaglia, J, Moss, S, Rush, J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am. J. Emerg. Med. 1997; 15(4): 335–340.CrossRefGoogle ScholarPubMed
Brook, S, Lucey, JV, Gunn, KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis: Ziprasidone I.M. Study Group. J. Clin. Psychiatry. 2000; 61(12): 933–941.CrossRefGoogle ScholarPubMed
Daniel, DG, Zimbroff, DL, Swift, RH, Harrigan, EP. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int. Clin. Psychopharmacol. 2004; 19(1): 9–15.CrossRefGoogle ScholarPubMed
Brook, S, Walden, J, Benattia, I, Siu, CO, Romano, SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl.). 2005; 178(4): 514–523.CrossRefGoogle Scholar
Wright, P, Meehan, K, Birkett, M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin. Ther. 2003; 25(5): 1420–1428.CrossRefGoogle ScholarPubMed
Andrezina, R, Marcus, RN, Oren, DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr. Med. Res. Opin. 2006; 22(11): 2209–2219.CrossRefGoogle ScholarPubMed
Lesem, MD, Zajecka, JM, Swift, RH, Reeves, KR, Harrigan, EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J. Clin. Psychiatry. 2001; 62(1): 12–18.CrossRefGoogle ScholarPubMed
Daniel, DG, Potkin, SG, Reeves, KR, Swift, RH, Harrigan, EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl.). 2001; 155(2): 128–134.CrossRefGoogle ScholarPubMed
Citrome, L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J. Clin. Psychiatry. 2007; 68(12): 1876–1885.CrossRefGoogle ScholarPubMed
Pfizer Inc. Geodon: US package insert for Geodon (ziprasidone HCl) capsules and Geodon (ziprasidone mesylate) injection for intramuscular use. September 2013. http://labeling.pfizer.com/ ShowLabeling.aspx?id=584. Accessed December 2, 2013.Google Scholar
Wright, P, Birkett, M, David, SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry. 2001; 158(7): 1149–1151.CrossRefGoogle Scholar
Breier, A, Meehan, K, Birkett, M, et al. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry. 2002; 59(5): 441–448.CrossRefGoogle Scholar
Meehan, K, Zhang, F, David, S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol. 2001; 21(4): 389–397.CrossRefGoogle Scholar
Meehan, KM, Wang, H, David, SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002; 26(4): 494–504.CrossRefGoogle ScholarPubMed
Andrezina, R, Josiassen, RC, Marcus, RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl.). 2006; 188(3): 281–292CrossRefGoogle ScholarPubMed
Tran-Johnson, TK, Sack, DA, Marcus, RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2007; 68(1): 111–119.CrossRefGoogle ScholarPubMed
Zimbroff, DL, Marcus, RN, Manos, G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J. Clin. Psychopharmacol. 2007; 27(2): 171–176.CrossRefGoogle ScholarPubMed
Rappaport, SA, Marcus, RN, Manos, G, McQuade, RD, Oren, DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. J. Am. Med. Dir. Assoc. 2009; 10(1): 21–27.CrossRefGoogle ScholarPubMed
Allen, MH, Feifel, D, Lesem, MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2011; 72(10): 1313–1321.CrossRefGoogle Scholar
Lesem, MD, Tran-Johnson, TK, Riesenberg, RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br. J. Psychiatry. 2011; 198(1): 51–58.CrossRefGoogle ScholarPubMed
Kwentus, J, Riesenberg, RA, Marandi, M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012; 14(1): 31–40.CrossRefGoogle Scholar
Citrome, L. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int. J. Clin. Pract. 2012; 66(3): 318–325.CrossRefGoogle ScholarPubMed
Citrome, L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther. Clin. Risk Manag. 2013; 9: 235–245.CrossRefGoogle ScholarPubMed
Merck & Co., Inc. Saphris: US package insert for Saphris (asenapine) sublingual tablets. March 2013. http://www.merck.com/product/usa/pi_circulars/s/saphris/saphris_pi.pdf. Accessed December 2, 2013.Google Scholar
Citrome, L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int. J. Clin. Pract. 2009; 63(12): 1762–1784.CrossRefGoogle Scholar
Pratts, M, Citrome, L, Grant, W, Leso, L, Opler, LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatrica Scand. 2014 Jul; 130(1): 61–68.CrossRefGoogle ScholarPubMed
Wilson, MP, Pepper, D, Currier, GW, Holloman, GH Jr, Feifel, D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West. J. Emerg. Med. 2012; 13(1): 26–34.CrossRefGoogle Scholar
Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 2008; 62(8): 1237–1245.CrossRefGoogle Scholar
Nolan, KA, Volavka, J, Czobor, P, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J. Psychiatr. Res. 2005; 39(1): 109–115.CrossRefGoogle ScholarPubMed
Nolan, KA, Volavka, J, Mohr, P, Czobor, P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr. Serv. 1999; 50(6): 787–792.CrossRefGoogle Scholar
Cooke, DJ, Michie, C. Refining the construct of psychopathy: towards a hierarchical model. Psychol. Assess. 2001; 13(2): 171–188.CrossRefGoogle ScholarPubMed
Nolan, KA, Czobor, P, Roy, BB, et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr. Serv. 2003; 54(7): 1012–1016.CrossRefGoogle ScholarPubMed
Citrome, L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev. Neurother. 2013; 13(7): 767–783.CrossRefGoogle ScholarPubMed
Volavka, J, Zito, JM, Vitrai, J, Czobor, P. Clozapine effects on hostility and aggression in schizophrenia. J. Clin. Psychopharmacol. 1993; 13(4): 287–289.CrossRefGoogle Scholar
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv. 2001; 52(11): 1510–1514.CrossRefGoogle ScholarPubMed
Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.CrossRefGoogle Scholar
Citrome, L. Clozapine for schizophrenia: life-threatening or life-saving treatment? Current Psychiatry. 2009; 8(12): 56–63.Google Scholar
Volavka, J, Czobor, P, Derks, EM, et al. EUFEST Study Group. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J. Clin. Psychiatry. 2011; 72(7): 955–961.CrossRefGoogle Scholar
Volavka, J, Czobor, P, Citrome, L, Van Dorn, RA. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. 2014; 0(5): 374–381. DOI: http://dx.doi.org/10.1017/S1092852913000849CrossRefGoogle Scholar
Kinon, BJ, Roychowdhury, SM, Milton, DR, Hill, AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J. Clin. Psychiatry. 2001; 62(Suppl 2): 17–21.Google Scholar
Citrome, L, Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.CrossRefGoogle Scholar
Citrome, L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev. Neurother. 2009; 9(1): 55–71.CrossRefGoogle Scholar
Citrome, L, Levine, J, Allingham, B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 2000; 51(5): 634–638.CrossRefGoogle ScholarPubMed
Citrome, L, Shope, CB, Nolan, KA, Czobor, P, Volavka, J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int. Clin. Psychopharmacol. 2007; 22(6): 356–362.CrossRefGoogle ScholarPubMed
Huband, N, Ferriter, M, Nathan, R, Jones, H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst. Rev. 2010;(2): CD003499.Google Scholar
Ratey, JJ, Sorgi, P, O'Driscoll, GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J. Clin. Psychiatry. 1992; 53(2): 41–46.Google ScholarPubMed
Alpert, M, Allan, ER, Citrome, L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol. Bull. 1990; 26(3): 367–371.Google ScholarPubMed
Caspi, N, Modai, I, Barak, P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int. Clin. Psychopharmacol. 2001; 16 (2): 111–115.CrossRefGoogle Scholar
References
Stahl, SM, Morrissette, DA, Citrome, L, et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013; 18(3): 150–162.CrossRefGoogle Scholar
Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev. Psiquiatr. Salud Ment. 2013; 6(3): 97–100.CrossRefGoogle ScholarPubMed
Citrome, L, Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.CrossRefGoogle ScholarPubMed
Warburton, K. The new mission of forensic mental health systems: managing violence as a medical syndrome in an environment that balances treatment and safety. CNS Spectr. 2014; 0(5): 368–373.CrossRefGoogle Scholar
Nolan, KA, Czobor, P, Roy, BB, et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr. Serv. 2003; 54(7): 1012–1016.CrossRefGoogle ScholarPubMed
Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 2008; 62 (8): 1237–1245.CrossRefGoogle Scholar
Volavka, J, Citrome, L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr. Bull. 2011; 37(5): 921–929.CrossRefGoogle ScholarPubMed
Swanson, JW, Swartz, MS, Van Dorn, RA, et al. Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br. J. Psychiatry. 2008; 193(1): 37–43.CrossRefGoogle ScholarPubMed
Quanbeck, CD, McDermott, BE, Lam, J, et al. Categorization of aggressive acts committed by chronically assaultive state hospital patients. Psychiatr. Serv. 2007; 58(4): 521–528.CrossRefGoogle ScholarPubMed
Stahl, SM. Stahl's Essential Psychopharmacology, 4th edn. New York: Cambridge University Press; 2013.Google Scholar
Stahl, SM, Morrissette, DA. Stahl's Illustrated Violence: Neural Circuits, Genetics, and Treatment. New York: Cambridge University Press; 2014.CrossRefGoogle Scholar
Siever, LJ. Neurobiology of aggression and violence. Am. J. Psychiatry. 2008; 165(4): 429–442.CrossRefGoogle Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine's anti-aggressive effects. Int. J. Neuropsychopharmacol. 2012; 15(9): 1351–1371.CrossRefGoogle ScholarPubMed
Coccaro, EF, McCloskey, MS, Fitzgerald, DA, Phan, KL. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression. Biol. Psychiatry. 2007; 62(2): 168–178.CrossRefGoogle Scholar
Coccaro, EF, Sripada, CS, Yanowitch, RN, Phan, KL. Corticolimbic function in impulsive aggressive behavior. Biol. Psychiatry. 2011; 69(12): 1153–1159.CrossRefGoogle ScholarPubMed
Bobes, J, Fillat, O, Arango, C. Violence among schizophrenia out-patients compliant with medication: prevalence and associated factors. Acta Psychiatr. Scand. 2009; 119(3): 218–225.CrossRefGoogle Scholar
Meyer, J. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr. 2014; 19(5): 432–438. DOI: http://dx.doi.org/10.1017/ S1092852914000236.CrossRefGoogle ScholarPubMed
Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr. Scand. 2012; 125(5): 349–351.CrossRefGoogle Scholar
Pavlov, KA, Chistiakov, DA, Chekhonin, VP. Genetic determinants of aggression and impulsivity in humans. J. Appl. Genet. 2012; 53(1): 61–82.CrossRefGoogle ScholarPubMed
Fazel, S, Grann M, Langstrom N. What is the role of epidemiology for forensic psychiatry? Crim. Behav. Ment. Health. 2009; 19(5): 281–285.CrossRefGoogle ScholarPubMed
Fazel, S, Gulati, G, Linsell, L, Geddes, JR, Grann, M. Schizophrenia and violence: systematic review and meta-analysis. PLoS Med. 2009; 6 (8): e1000120.CrossRefGoogle Scholar
Fazel, S, Langstrom, N, Hjern, A, Grann, M, Lichtenstein, P. Schizophrenia, substance abuse, and violent crime. JAMA. 2009; 301(19): 2016–2023.CrossRefGoogle ScholarPubMed
Topiwala, A, Fazel, S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev. Neurother. 2011; 11(1): 53–63.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P. Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial. J. Clin. Psychiatry. 2012; 73(1): 74–80.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol. 2008; 28(5): 485–493.CrossRefGoogle Scholar
Singh, JP, Grann, M, Fazel, S. A comparative study of violence risk assessment tools: a systematic review and metaregression analysis of 68 studies involving 25,980 participants. Clin. Psychol. Rev. 2011; 31(3): 499–513.CrossRefGoogle ScholarPubMed
Song, H, Min, SK. Aggressive behavior model in schizophrenic patients. Psychiatry Res. 2009; 167(1–2): 58–65.CrossRefGoogle ScholarPubMed
Uchida, H, Takeuchi, H, Graff-Guerrero, A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011; 31(4): 497–502.CrossRefGoogle ScholarPubMed
Correll, CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry. 2010; 25(Suppl 2): S12–S21.CrossRefGoogle ScholarPubMed
Nord, M, Farde, L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011; 17(2): 97–103.CrossRefGoogle Scholar
Uchida, H, Takeuchi, H, Graff-Guerrero, A, et al. Predicting dopamine D receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011; 31(3): 318–325.CrossRefGoogle ScholarPubMed
Stauffer, V, Case, M, Kollack-Walker, S, et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr. Res. 2011; 130(1–3): 11–19.CrossRefGoogle ScholarPubMed
Robinson, DG, Woerner, MG, Alvir, JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 1999; 156(4): 544–549.Google ScholarPubMed
Stahl, SM. Stahl's Essential Psychopharmacology, 3rd edn. New York: Cambridge University Press; 2008.Google Scholar
Morrissette, DA, Stahl, SM. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. CNS Spectr. 2012; 17 (Suppl 1): 10–21.CrossRefGoogle ScholarPubMed
Ritsner, MS, ed. Polypharmacy in Psychiatric Practice, Volume I: Multiple Medication Use Strategies. New York: Springer Verlag; 2013.CrossRefGoogle Scholar
Ritsner, MS, ed. Polypharmacy in Psychiatric Practice, Volume II: Use of Polypharmacy in the "Real World". New York: Springer Verlag; 2013.CrossRefGoogle Scholar
Stentebjerg-Olesen, M, Jeppesen, P, Pagsberg, AK, et al. Early nonresponse determined by the Clinical Global Impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics. J. Child Adolesc. Psychopharmacol. 2013; 23(10): 665–675.CrossRefGoogle Scholar
Mauri, MC, Volonteri, LS, Colasanti, A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin. Pharmacokinet. 2007; 46(5): 359–388.CrossRefGoogle ScholarPubMed
Remington, G, Kapur, S. Antipsychotic dosing: how much but also how often? Schizophr. Bull. 2010; 36(5): 900–903.CrossRefGoogle Scholar
Samaha, AN, Seeman, P, Stewart, J, Rajabi, H, Kapur, S. “Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J. Neurosci. 2007; 27(11): 2979–2986.CrossRefGoogle ScholarPubMed
Seeman, P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses. 2010; 4(1): 56–73.CrossRefGoogle Scholar
Davis, JM, Chen, N. Dose response and dose equivalence of antipsychotics. J. Clin. Psychopharmacol. 2004; 24(2): 192–208.CrossRefGoogle Scholar
Krakowski, MI, Kunz, M, Czobor, P, Volavka, J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp. Community Psychiatry. 1993; 44(7): 640–644.Google Scholar
Gisev, N, Bell, JS, Chen, TF. Factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals receiving compulsory treatment in the community. J. Clin. Psychopharmacol. 2014; 34(3): 307–312.CrossRefGoogle Scholar
Roh, D, Chang, JG, Kim, CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust. N. Z. J. Psychiatry. 2014; 48(1): 52–60.CrossRefGoogle Scholar
Barnes, TR, Paton, C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 2011; 25(5): 383–399.CrossRefGoogle Scholar
Fleischhacker, WW, Uchida, H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2014; 17(7): 1083–1093.CrossRefGoogle ScholarPubMed
Fujita, J, Nishida, A, Sakata, M, Noda, T, Ito, H. Excessive dosing and polypharmacy of antipsychotics caused by prorenata in agitated patients with schizophrenia. Psychiatry Clin. Neurosci. 2013; 67(5): 345–351.CrossRefGoogle Scholar
Gallego, JA, Bonetti, J, Zhang, J, Kane, JM, Correll, CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr. Res. 2012; 138(1): 18–28.CrossRefGoogle ScholarPubMed
Lochmann van Bennekom, MWH, Gijsman, HJ, Zitman, FG. Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness. J. Psychopharmacol. 2013; 27(4): 327–336.CrossRefGoogle ScholarPubMed
Sagud, M, Vuksan-Cusa, B, Zivkovic, M, et al. Antipsychotics: to combine or not to combine? Psychiatr. Danub. 2013; 25(3): 306–310.Google ScholarPubMed
Suokas, JT, Suvisaari, JM, Haukka, J, Korhonen, P, Tiihonen, J. Description of long-term polypharmacy among schizophrenia outpatients. Soc. Psychiatry Psychiatr. Epidemiol. 2013; 48(4): 631–638.CrossRefGoogle ScholarPubMed
Freudenreich, O, Goff, DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr. Scand. 2002; 106(5): 323–330.CrossRefGoogle ScholarPubMed
Goren, JL, Meterko, M, Williams, S, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr. Serv. 2013; 64(6): 527–533.CrossRefGoogle Scholar
Englisch, S, Zink, M. Treatment-resistant schizophrenia: evidence-based strategies. Mens Sana Monogr. 2012; 10(1): 20–32.Google ScholarPubMed
Langle, G, Steinert, T, Weiser, P, et al. Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr. Scand. 2012; 125(5): 372–381.CrossRefGoogle ScholarPubMed
Essock, SM, Schooler, NR, Stroup, TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry. 2011; 168(7): 702–708.CrossRefGoogle ScholarPubMed
Stahl, SM, Grady, MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr. Med. Chem. 2004; 11(3): 313–327.CrossRefGoogle ScholarPubMed
Stahl, SM. Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int. J. Neuropsychopharmacol. 2004; 7(2): 113–116.CrossRefGoogle ScholarPubMed
Stahl, SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiatr. Scand. 2002; 106(5): 321–322.CrossRefGoogle ScholarPubMed
Stahl, SM. Antipsychotic polypharmacy: squandering precious resources? J. Clin. Psychiatry. 2002; 63(2): 93–94.CrossRefGoogle Scholar
Stahl, SM. Antipsychotic polypharmacy, part 2: tips on use and misuse. J. Clin. Psychiatry. 1999; 60(8): 506–507.CrossRefGoogle ScholarPubMed
Stahl, SM. Antipsychotic polypharmacy, part 1: therapeutic option or dirty little secret? J. Clin. Psychiatry. 1999; 60(7): 425–426.CrossRefGoogle ScholarPubMed
Stahl, SM. “Awakening” from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. J. Clin. Psychiatry. 1997; 58(9): 381–382.CrossRefGoogle ScholarPubMed
Suzuki, T, Uchida, H, Tanaka, KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int. J. Neuropsychopharmacol. 2004; 7(2): 133–142.CrossRefGoogle Scholar
Correll, CU, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009; 35(2): 443–457.CrossRefGoogle ScholarPubMed
Iasevoli, F, Buonaguro, EF, Marconi, M, et al. Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study. ISRN Pharmacology. 2014; 2014: 762127.CrossRefGoogle Scholar
Coccaro, EF. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5. Am. J. Psychiatry. 2012; 169(6): 577–588.CrossRefGoogle ScholarPubMed
Rosell, DR, Thompson, JL, Slifstein, M, et al. Increased serotonin 2A receptor availability in the orbitofrontal cortex of physically aggressive personality disordered patients. Biol. Psychiatry. 2010; 67(12): 1154–1162.CrossRefGoogle ScholarPubMed
Winstanley, CA, Theobald, DE, Dalley, JW, Glennon, JC, Robbins, TW. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl.). 2004; 176(3–4): 376–385.CrossRefGoogle ScholarPubMed
Englisch, S, Zink, M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008; 32(6): 1386–1392.CrossRefGoogle ScholarPubMed
Katona, L, Czobor, P. Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr. Res. 2014; 152(1): 246–254.CrossRefGoogle Scholar
Ballon, J, Stroup, TS. Polypharmacy for schizophrenia. Curr. Opin. Psychiatry. 2013; 26(2): 208–213.CrossRefGoogle Scholar
Fleischhacker, WW, Heikkinen, ME, Olie, JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int. J. Neuropsychopharmacol. 2010; 13(8): 1115–1125.CrossRefGoogle ScholarPubMed
Chang, JS, Ahn, YM, Park, HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2008; 69(5): 720–731.CrossRefGoogle ScholarPubMed
Thompson, C. The use of high-dose antipsychotic medication. Br. J. Psychiatry. 1994; 164(4): 448–458.CrossRefGoogle ScholarPubMed
Schwartz, TL, Stahl, SM. Treatment strategies for dosing the second generation antipsychotics. CNS Neurosci. Ther. 2011; 17(2): 110–117.CrossRefGoogle Scholar
Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.CrossRefGoogle ScholarPubMed
Kantrowitz, JT, Citrome, L. Lurasidone for schizophrenia: what's different? Expert Rev. Neurother. 2012; 12(3): 265–273.CrossRefGoogle ScholarPubMed
Aggarwal, NK, Sernyak, MJ, Rosenheck, RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J. Clin. Psychopharmacol. 2012; 32(3): 323–328.CrossRefGoogle Scholar
Elie, D, Poirier, M, Chianetta, J, et al. Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J. Psychopharmacol. 2010; 24(7): 1037–1044.CrossRefGoogle ScholarPubMed
Hiemke, C, Baumann, P, Bergemann, N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011; 44(6): 195–235.Google ScholarPubMed
Potkin, SG, Keator, DB, Kesler-West, ML, et al. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014; 19(2): 176–181.CrossRefGoogle ScholarPubMed
References
Bollini, P, Andreani, A, Colombo, F, et al. High-dose neuroleptics: uncontrolled clinical practice confirms controlled clinical trials. Br. J. Psychiatry. 1984; 144(1): 25–27.CrossRefGoogle ScholarPubMed
Mackay, AVP. High-dose antipsychotic medication. Advances in Psychiatric Treatment. 1994; 1(1): 16–23.CrossRefGoogle Scholar
Krakowski, MI, Kunz, M, Czobor, P, Volavka, J. Long-term high-dose neuroleptic treatment: who gets it and why? Hosp. Community Psychiatry. 1993; 44(7): 640–644.Google Scholar
Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int. J. Neuropsychopharmacol.. 2012; 15(9): 1351–1371.CrossRefGoogle ScholarPubMed
Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.CrossRefGoogle ScholarPubMed
Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication. Council Report CR138. London: Royal College of Psychiatrists; 2006.Google Scholar
Paton, C, Barnes, TR, Cavanagh, MR, Taylor, D, Lelliott, P; POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br. J. Psychiatry. 2008; 192(6): 435–439.CrossRefGoogle Scholar
Meyer, JM. Drug–drug interactions with antipsychotics. CNS Spectr. 2007; 12(Suppl 21): 6–9.CrossRefGoogle ScholarPubMed
Kirchheiner, J, Schmidt, H, Tzvetkov, M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007; 7(4): 257–265.CrossRefGoogle Scholar
Uchida, H, Takeuchi, H, Graff-Guerrero, A, et al. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011; 31(3): 318–325.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.CrossRefGoogle ScholarPubMed
Krakowski, MI, Czobor, P, Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J. Clin. Psychopharmacol. 2008; 28(5): 485–493.CrossRefGoogle Scholar
Glick, ID, Balon, RJ, Ballon, J, Rovine, D. Teaching pearls from the lost art of psychopharmacology. J. Psychiatr. Pract. 2009; 15(5): 423–426.CrossRefGoogle ScholarPubMed
Simpson, GM, Kunz-Bartholini, E. Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis. Nerv. Syst. 1968; 29(4): 269–274.Google ScholarPubMed
Merck under license to Forest Pharmaceuticals. Saphris [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014.Google Scholar
Sunovion Pharmaceuticals, Inc. Latuda [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc.; 2013.Google Scholar
Haslemo, T, Olsen, K, Lunde, H, Molden, E. Valproic acid significantly lowers serum concentrations of olanzapine – an interaction effect comparable with smoking. Ther. Drug Monit. 2012; 34(5): 512–517.CrossRefGoogle ScholarPubMed
Longo, LP, Salzman, C. Valproic acid effects on serum concentrations of clozapine and norclozapine. Am. J. Psychiatry. 1995; 152(4): 650.Google ScholarPubMed
Coryell, W, Miller, DD, Perry, PJ. Haloperidol plasma levels and dose optimization. Am. J. Psychiatry. 1998; 155(1): 48–53.CrossRefGoogle ScholarPubMed
Midha, KK, Hubbard, JW, Marder, SR, Marshall, BD, Van Putten, T. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J. Psychiatry. Neurosci. 1994; 19(4): 254–264.Google ScholarPubMed
Perry, PJ, Lund, BC, Sanger, T, Beasley, C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J. Clin. Psychopharmacol. 2001; 21(1): 14–20.CrossRefGoogle ScholarPubMed
Gefvert, O, Eriksson, B, Persson, P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol. 2005; 8(1): 27–36.CrossRefGoogle Scholar
Mamo, D, Kapur, S, Keshavan, M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008; 33(2): 298–304.CrossRefGoogle ScholarPubMed